Lipocine rallies after therapy candidate achieves meaningful liver fat reduction
Lipocine Inc (NASDAQ:LPCN) surged Thursday after reporting that interim results showed its therapy candidate for non-alcoholic steatohepatitis (NASH) achieved meaningful liver fat reduction.
The specialty drug company announced the interim results after about eight weeks of an ongoing 16-week study of LPCN 1144. The therapy candidate produced an absolute mean reduction from baseline of 7.6% liver fat and a 38% relative mean liver fat reduction, according to Lipocine.
Shares of Salt Lake City-based Lipocine rose $0.39, or 25%, to $1.99 in Thursday’s Nasdaq trading.
READ: Lipocine’s LPCN 1111 Phase 2b clinical study kicks off
The company said there was an 86% responder rate in which subjects experienced at least a 4.1% absolute reduction in liver fat from baseline and a 71% responder rate in which subjects experienced at least a 29% reduction in liver fat from baseline.
The ongoing liver fat study is an open-label, multi-center, single-arm study evaluating the treatment of 36 hypogonadal males, lacking sufficient testosterone or having an impaired ability to produce sperm.
Non-alcoholic steatohepatitis is an advanced form of non-alcoholic fatty liver disease that occurs when fat accumulates in liver cells from causes other than excessive alcohol use. Patients have hepatitis (inflammation of the liver) and liver cell damage.
CEO encouraged by results
“We are very encouraged by these results especially as the observed liver fat reductions are the largest of any well-tolerated oral product candidate within approximately eight weeks,” Dr Mahesh Patel, the chairman, president and CEO of Lipocine, said in a statement. “We look forward to the 16-week results later this quarter.”
He added that he believes LPCN 1144 can offer additional unmet benefits such as improvement for patients with cardiovascular disease, sarcopenia and sexual dysfunction.
There are no approved treatments of NASH, according to Lipocine, which says the illness is a silent killer that affects 30 million Americans.
Contact Dennis Fitzgerald at [email protected]
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/212829/lipocine-rallies-after-therapy-candidate-achieves-meaningful-liver-fat-reduction-212829.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).